为跨性别患者开处方。
Prescribing for transgender patients.
作者信息
Tomlins Louise
机构信息
Taylor Square Private Clinic, Sydney.
出版信息
Aust Prescr. 2019 Feb;42(1):10-13. doi: 10.18773/austprescr.2019.003. Epub 2019 Feb 1.
Abstract
With greater awareness and social acceptance, increasing numbers of transgender individuals are presenting for gender-affirming hormone treatment. There should be a full psychosocial assessment by an experienced clinician before hormone treatment is considered People assigned as males at birth who transition to female gender are transgender females. Their management includes an estrogen plus an anti-androgen People assigned as females at birth who transition to male gender are transgender males. Their hormone treatment is testosterone Treatment is titrated so that hormone concentrations are equivalent to the physiological concentrations of the preferred gender. This aims to minimise adverse effects
摘要
随着意识的提高和社会的接纳，越来越多的跨性别者寻求性别确认激素治疗。在考虑激素治疗之前，应由经验丰富的临床医生进行全面的心理社会评估。出生时被认定为男性但转变为女性性别的人是跨性别女性。她们的治疗包括雌激素加抗雄激素。出生时被认定为女性但转变为男性性别的人是跨性别男性。他们的激素治疗是使用睾酮。治疗需进行滴定，以使激素浓度等同于所期望性别的生理浓度。这旨在将不良反应降至最低。
相似文献
1
Prescribing for transgender patients.为跨性别患者开处方。
Aust Prescr. 2019 Feb;42(1):10-13. doi: 10.18773/austprescr.2019.003. Epub 2019 Feb 1.
2
MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.内分泌疾病管理：跨性别者的最佳女性激素治疗。
Eur J Endocrinol. 2021 Jun 28;185(2):R49-R63. doi: 10.1530/EJE-21-0059.
3
Gender-affirming hormone treatment causes changes in gender phenotype in a 12-lead electrocardiogram.性别肯定激素治疗会导致 12 导联心电图中性别表型的变化。
Heart Rhythm. 2021 Jul;18(7):1203-1209. doi: 10.1016/j.hrthm.2021.03.009. Epub 2021 Mar 8.
4
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.性别焦虑/性别不一致者的内分泌治疗：内分泌学会临床实践指南
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658.
5
SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.接受性别肯定激素治疗的跨性别个体的血清激素浓度：一项纵向回顾性队列研究。
Endocr Pract. 2021 Jan;27(1):27-33. doi: 10.4158/EP-2020-0414. Epub 2020 Nov 18.
6
Assessment of Gender-Affirming Hormone Therapy Requirements.评估性别肯定激素治疗需求。
LGBT Health. 2019 Apr;6(3):101-106. doi: 10.1089/lgbt.2018.0116. Epub 2019 Feb 27.
7
Dynamic Gender Presentations: Understanding Transition and "De-Transition" Among Transgender Youth.动态性别表达：理解跨性别青年的转变和“去转变”。
J Am Acad Child Adolesc Psychiatry. 2018 Jul;57(7):451-453. doi: 10.1016/j.jaac.2018.03.016.
8
Impact of Early Medical Treatment for Transgender Youth: Protocol for the Longitudinal, Observational Trans Youth Care Study.早期医疗干预对跨性别青少年的影响：纵向观察性跨性别青少年护理研究方案
JMIR Res Protoc. 2019 Jul 9;8(7):e14434. doi: 10.2196/14434.
9
Hormone Therapy for Transgender Adults.跨性别成年人的激素治疗。
Urol Clin North Am. 2019 Nov;46(4):467-473. doi: 10.1016/j.ucl.2019.07.001. Epub 2019 Aug 19.
10
Cross-sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare.澳大利亚的跨性别激素治疗：有成人跨性别者医疗护理经验的临床医生的处方模式。
Intern Med J. 2019 Feb;49(2):182-188. doi: 10.1111/imj.14035.
引用本文的文献
1
Cross-Sex Hormone Therapy Is Associated With Loss of Circadian Rhythm in the Male Rat.跨性别激素疗法与雄性大鼠昼夜节律丧失有关。
Hypertension. 2025 Feb;82(2):241-254. doi: 10.1161/HYPERTENSIONAHA.124.23901. Epub 2024 Dec 5.
2
Endocrine, gender dysphoria, and sexual function benefits of gender-affirming bilateral orchiectomy: patient outcomes and surgical technique.性别肯定性双侧睾丸切除术的内分泌、性别焦虑及性功能益处：患者结局与手术技术
Sex Med. 2024 Aug 29;12(4):qfae048. doi: 10.1093/sexmed/qfae048. eCollection 2024 Aug.
3
Risk assessment of transgender people: implementation of a demasculinizing-feminizing rodent model including the evaluation of thyroid homeostasis.跨性别者风险评估：去势-女性化啮齿动物模型的实施，包括甲状腺内稳态的评估。
Biol Direct. 2024 Jan 2;19(1):5. doi: 10.1186/s13062-023-00450-1.
4
Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.评估和应对跨性别肯定护理谱中的静脉血栓栓塞风险：综述。
Endocr Pract. 2023 Apr;29(4):272-278. doi: 10.1016/j.eprac.2022.12.008. Epub 2022 Dec 17.
5
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.跨性别女性中替诺福韦、恩曲他滨和细胞内代谢物的群体药代动力学。
Br J Clin Pharmacol. 2022 Aug;88(8):3674-3682. doi: 10.1111/bcp.15310. Epub 2022 Mar 25.
6
A link between migraine and prolactin: the way forward.偏头痛与催乳素之间的联系：未来的方向。
Future Sci OA. 2021 Sep 22;7(9):FSO748. doi: 10.2144/fsoa-2021-0047. eCollection 2021 Oct.
7
IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Reaffirmation as Female.IDEA 小组关于寻求女性性别肯定的成年性别不一致个体的医学管理的共识声明。
Indian J Endocrinol Metab. 2020 Mar-Apr;24(2):128-135. doi: 10.4103/ijem.IJEM_593_19. Epub 2020 Apr 30.
本文引用的文献
1
Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents.澳大利亚为跨性别和性别多样化儿童及青少年提供的护理和治疗标准及指导原则。
Med J Aust. 2018 Aug 6;209(3):132-136. doi: 10.5694/mja17.01044. Epub 2018 Jun 18.
2
Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.性别焦虑/性别不一致者的内分泌治疗：内分泌学会临床实践指南
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. doi: 10.1210/jc.2017-01658.
3
The health and well-being of transgender high school students: results from the New Zealand adolescent health survey (Youth'12). transgender 高中生的健康和幸福：来自新西兰青少年健康调查（Youth'12）的结果。
J Adolesc Health. 2014 Jul;55(1):93-9. doi: 10.1016/j.jadohealth.2013.11.008. Epub 2014 Jan 14.
4
Interpreting laboratory results in transgender patients on hormone therapy.解读接受激素治疗的跨性别患者的实验室检查结果。
Am J Med. 2014 Feb;127(2):159-62. doi: 10.1016/j.amjmed.2013.10.009. Epub 2013 Oct 19.
Zotero 插件